Prof . Dalia Saleh | National Research Centre | Egypt
Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist with over two decades of experience in experimental pharmacology and drug development. She holds a Ph.D. in Pharmacology from Cairo University and currently serves as a Professor at the National Research Centre in Cairo, Egypt. Dr. Saleh has contributed to numerous high-impact scientific journals and has led pioneering work in the areas of metabolic disorders, drug safety, and vascular pharmacology. Her multidisciplinary collaborations and continuous professional development from institutions like King’s College London demonstrate her dedication to excellence in research and education. She is also recognized for her commitment to academic instruction and quality assurance, having served as a Quality Assurance Director. Her work bridges scientific discovery and real-world therapeutic applications, making her a strong candidate for innovation-focused research awards.
publication profile:
scopus
Strengths for the Award:
-
Robust Academic Background:
Dr. Saleh holds a Ph.D. in Pharmacology from Cairo University and has a long-standing academic and research career in pharmacology and drug development. Her doctoral and master’s theses reflect a strong foundation in vascular pharmacology, metabolic disorders, and endocrine influence—fields of enduring relevance.
-
Consistent Research Productivity:
Her recent publication record (2022–2024) is prolific and impactful, with studies published in high-visibility journals such as Scientific Reports, Biochemistry and Cell Biology, Naunyn-Schmiedeberg’s Archives of Pharmacology, and Environmental Science and Pollution Research. Her work covers cutting-edge pharmacological topics, including:
-
AMPK/mTOR signaling pathways,
-
Neuroprotection and anti-inflammatory mechanisms,
-
Herbal and synthetic compounds in disease modulation,
-
Hepatic encephalopathy, diabetic nephropathy, and cystitis models.
-
Interdisciplinary and Translational Approach:
Dr. Saleh bridges basic pharmacological research with clinical relevance. Her investigations into molecular pathways (e.g., NF-κB, PI3K/Akt, SIRT-1) are grounded in disease models, thus demonstrating translational potential. Her inclusion of both natural and synthetic agents further adds diversity and innovation to her research.
-
Capacity Building and International Exposure:
She has participated in Continuing Professional Development modules at King’s College London, emphasizing drug safety, statistics, and ethics—key areas in modern drug development. This international engagement underscores her commitment to staying updated and aligned with global standards.
-
Institutional Contribution and Leadership:
As a Professor and former Quality Assurance Director at the National Research Centre (NRC), she has contributed to institutional excellence, including achieving ISO 9001/2008 certification. These roles reflect her leadership, organizational, and strategic planning skills.
Areas for Improvement:
-
Principal Investigator Leadership:
While her name appears consistently in multi-author studies, further highlighting her role as the principal investigator (PI) or corresponding author could strengthen her case for innovation leadership.
-
Patents or Product Development:
There is no mention of patents or direct product development based on her findings. Translating research into tangible therapeutics or clinical trials would significantly elevate her eligibility for innovation-specific awards.
-
Global Collaborations and Grants:
Although she has participated in international seminars, active global collaborations or leading major international grants/projects would further establish her as a global innovator.
-
Public/Industry Impact:
While the academic impact is strong, showcasing industry partnerships or policy-level influence (e.g., contributions to clinical guidelines or regulatory science) would align more directly with innovation awards that emphasize practical application.
🎓 Education Summary :
Dr. Dalia Saleh completed her higher education at Cairo University’s Faculty of Pharmacy, where she earned her Master of Science in Pharmacology in 2009 and Doctor of Philosophy in Pharmacology in 2012. Her M.Sc. thesis focused on the vascular and biochemical effects of rosiglitazone in diabetic rats, reflecting early interests in metabolic pharmacology. Her Ph.D. expanded on this foundation by exploring estrogen’s potential role in managing vascular changes related to insulin resistance. Both theses demonstrated robust experimental designs and contributed new insights into the interplay between hormonal and metabolic pathways in disease models. Dr. Saleh has since built on this academic background with advanced training in clinical drug development, safety, and biostatistics at King’s College London in 2023, indicating a continued commitment to integrating modern pharmaceutical science and translational research into her academic portfolio. This rich educational foundation underpins her success as a researcher and educator.
🔬 Research Focus :
Dr. Saleh’s research focuses on experimental pharmacology, with a special interest in metabolic diseases, drug-induced toxicities, inflammation, and vascular pharmacology. Her studies frequently involve animal models to investigate the mechanisms of drug action and to evaluate the protective or therapeutic roles of natural products and synthetic compounds. A recurring theme in her work is exploring the modulation of signaling pathways like AMPK, NF-κB, PI3K/mTOR, and Nrf2 in the context of oxidative stress, inflammation, and cellular apoptosis. She has also studied the role of hormonal influences in disease models, such as estrogen’s effect on insulin resistance. Her research employs modern analytical techniques and integrates molecular biology with pharmacodynamics to derive mechanistic insights. This strong focus on mechanistic pharmacology enhances her work’s relevance in drug development, particularly for conditions such as diabetic complications, hepatic encephalopathy, nephropathy, and chemotherapy-induced toxicities.
📚 Publications Top Note:
-
🧪 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR modulation – Scientific Reports, 2024
-
🧠 Trimetazidine prevents cisplatin neuropathy through AMPK, Nrf2, and NF-κB pathways – Biochemistry and Cell Biology, 2023
-
🔬 Novel chromone-thiazolopyrimidines as TNF-α, IL-6, and PGE2 inhibitors – Polycyclic Aromatic Compounds, 2023
-
🚽 Chrysin protects against cyclophosphamide-induced hemorrhagic cystitis via anti-inflammatory signaling – Chemico-Biological Interactions, 2023
-
🧃 Linagliptin & L-arginine synergy in gastric hyperacidity via EP4 receptor upregulation – Naunyn-Schmiedeberg’s Archives of Pharmacology, 2023
-
🧠 L-arginine reduces thioacetamide-induced hepatic encephalopathy via NF-κB downregulation – Environmental Science and Pollution Research, 2023
-
🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activity – Arabian Journal of Chemistry, 2022
-
🛡️ Olmesartan mitigates diabetic nephropathy via AGE/PKC and TLR4/SIRT-1 pathways – European Journal of Pharmacology, 2022
-
🍃 Plumbago species show anti-fibrotic effects in liver fibrosis rat models – Scientific Reports, 2022
-
🫀 Omega-3 combats doxorubicin-induced liver toxicity via Nrf2/PI3K/Akt signaling – Pending Publication
Conclusion:
Dr. Dalia O. Saleh presents a strong candidacy for the Research for Innovative Research Award, particularly due to her sustained publication record, mechanistic depth in pharmacology, and commitment to professional development and institutional excellence. Her work spans innovative mechanistic explorations and novel therapeutic evaluations, showing real promise in addressing current pharmacological challenges.